GermanyGermany

Germany’s biotech sector grows despite financial crisis

08.05.2009

Berlin – Despite the financial crisis, the German biotech sector has grown moderately in 2008: turnover was again above EUR2bn (+9%) and expenditure for R&D rose above EUR1bn (+1.1%). While the number of dedicated biotech companies, remained about the same at 501, there was a slight increase in the number of employees. These are the main results of the company survey conducted by the information platform biotechnologie.de on behalf of the Federal Ministry of Education and Research (BMBF). The "Biotechnology Company Survey 2009" was officially introduced on May 6th. The data of this comprehensive annual survey were collected along the guidelines of the Organisation for Economic Co-operation and Development (OECD) and present an overview of the German biotech landscape.
Peter Heinrich, spokesman of the BIO Germany management board, emphasised, that in light of the current situation, by international comparison the German biotech sector is still looking relatively good. In the next three years, the industry will need at least one billion euros of equity to follow through with projects currently in company pipelines, finance innovative start-ups, and not be left behind internationally. "We welcome the Federal Ministry of Finance´s initiative to take back parts of the business tax reform", said Peter Heinrich.
The consultancy Ernst&Young released the results of their own assessment of the biotech sector at the same time as biotechnologie.de. The "Biotechnology-Report 2009" confirms the trends elucidated by biotechnologie.de regarding turnover and the number of employees. However, Ernst&Young only includes about 400 companies in their survey due to a non-OECD biotechnology definition. According to the report, the number of candidates in drug development from German biotech companies has slightly increased from 303 to 308. There are some more drug candidates, 139, in clinical trials Phases I to III as in the previous year with 129. Currently, there are five candidates awaiting approval – compared to seven last year. The decrease is also a result of the successful authorisation of three new drugs.

GermanyGermany

07.03.2012

The first of February marked a milestone for Leverkusen-based Bio­frontera AG in more ways than one. It was the first day that Ameluz, the firm’s first approved product, could be sold in German pharmacies. It was also the date...

GermanyGermany

07.03.2012

Darmstadt – German pharmaceutical and chemical company Merck KGaA has set a downbeat tone for 2012. CEO Karl-Ludwig Kley said the recently launched cost-cutting programme and tough economic conditions will weigh on profits this...

GermanyGermany

05.03.2012

Mainz/Leuna – Two biotech concepts were amongst the winners of the recent third round of the Excellence Cluster initiative, which is funded by the German Ministry for Research. In Mainz the champagne corks popped especially loud...

GermanyGermany

05.03.2012

German Merck KGaA has closed a licencing agreement with US-based Threshold Pharmaceuticals Inc. The cooperation centres around the hypoxia­-activated drug TH-302, which is currently being studied in a global Phase III study....

GermanyGermany

29.02.2012

Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight. The 2011 total revenue was...

GermanyGermany

17.02.2012

Brussels – European cartilage researchers intensify their cooperation. The 'gristle network' comprises scientists from Belgium, France, Germany and Luxembourg. Its members plan to meet regularly to exchange views and information...

27.01.2012

Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad news at the same time. Amgen Inc., the world's largest biotechnology company, agreed to buy Micromet Inc., an...

GermanyGermany

20.01.2012

Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a mere 43% rise at the end of the day. SHELTER is a...

GermanyGermany

17.01.2012

Ludwigshafen – BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next two years, most of the green biotechnology...

GermanyGermany

10.01.2012

Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the renowned US...

Displaying results 1 to 10 out of 454

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/article/germanys-biotech-sector-grows-despite-financial-crisis.html

Product of the week

Products

Events

All Events

Current issue

All issues